StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.54−0.03 (-5.26%)

Close on Nov 18, 2026Market cap $2.17MP/E –Yield –

Dermata Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for Dermata Therapeutics

Dermata Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Dermata Therapeutics figures

See a number that looks wrong?